This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

HEXO Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für HEXO zu prognostizieren.

Wichtige Informationen

83.6%

Wachstumsrate der Gewinne

85.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	53.6%
Wachstumsrate der Einnahmen	-0.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Jun 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Bearish: Analysts Just Cut Their HEXO Corp. (TSE:HEXO) Revenue and EPS estimates

Mar 21

Gewinn- und Umsatzwachstumsprognosen

TSX:HEXO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
7/31/2025	121	-19	48	40	2
7/31/2024	108	-24	35	23	2
7/31/2023	103	-198	-4	16	2
4/30/2023	124	-273	-48	-39	N/A
1/31/2023	148	-301	-63	-48	N/A
10/31/2022	177	-1,013	-101	-89	N/A
7/31/2022	191	-1,074	-151	-117	N/A
4/30/2022	187	-1,042	-181	-127	N/A
1/31/2022	164	-918	-169	-121	N/A
10/31/2021	144	-228	-148	-93	N/A
7/31/2021	124	-115	-75	-43	N/A
4/30/2021	112	-214	-41	-18	N/A
1/31/2021	112	-213	-66	-23	N/A
10/31/2020	96	-491	-133	-66	N/A
7/31/2020	81	-546	-204	-95	N/A
4/30/2020	69	-423	-307	-174	N/A
1/31/2020	60	-411	-324	-175	N/A
10/31/2019	56	-117	-299	-138	N/A
7/31/2019	48	-70	-266	-125	N/A
4/30/2019	34	-35	-182	-55	N/A
1/31/2019	22	-30	-155	-51	N/A
10/31/2018	9	-34	-110	-42	N/A
7/31/2018	5	-23	-70	-22	N/A
4/30/2018	4	-12	-39	-13	N/A
1/31/2018	4	-22	-22	-10	N/A
10/31/2017	4	-14	-14	-6	N/A
7/31/2017	4	-12	-9	-5	N/A
4/30/2017	4	-15	-8	-4	N/A
1/31/2017	4	-3	N/A	-4	N/A
10/31/2016	3	-3	N/A	-3	N/A
7/31/2016	2	-3	N/A	-3	N/A
7/31/2015	0	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HEXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: HEXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: HEXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: HEXODie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-0.7% pro Jahr).

Hohe Wachstumseinnahmen: HEXODie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-0.7% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HEXO in 3 Jahren voraussichtlich hoch sein wird

This company has been acquired

HEXO Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to CA$0.81 loss, revenue downgraded

Price target decreased by 22% to CA$1.64

Price target decreased by 9.1% to CA$1.95

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 11% to CA$2.28

Consensus revenue estimates fall by 17%

Recent updates

HEXO Corp.(NasdaqCM:HEXO) dropped from NASDAQ Composite Index

HEXO Corp. announced that it has received $25 million in funding

Consensus EPS estimates upgraded to CA$0.81 loss, revenue downgraded

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

HEXO Corp. to Report Q3, 2023 Results on Jun 14, 2023

Price target decreased by 22% to CA$1.64

Price target decreased by 9.1% to CA$1.95

Consensus revenue estimates decrease by 27%, EPS upgraded

Bearish: Analysts Just Cut Their HEXO Corp. (TSE:HEXO) Revenue and EPS estimates

Price target decreased by 11% to CA$2.28

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

HEXO Corp. Launches Enhanced Inhalation Technology

HEXO Corp Wins Complete Dismissal of Putative Québec Shareholder Class Action

HEXO Launches Five New Cannabis Strains Under Market-Leading Redecan and Original Stash Brands

Consensus revenue estimates fall by 17%

Price target decreased to CA$0.20

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HEXO Corp., Annual General Meeting, Jan 31, 2023

Consensus EPS estimates fall by 12%

High number of new and inexperienced directors

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Sundial Growers Inc. (NasdaqCM:SNDL) acquired Zenabis Global Inc. from HEXO Corp. (TSX:HEXO).

No longer forecast to breakeven

HEXO Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Price target decreased to CA$0.29

High number of new and inexperienced directors

HEXO Corp. has completed a Follow-on Equity Offering in the amount of $40 million.

Sundial Growers Inc. (NasdaqCM:SNDL) entered into a purchase agreement to acquire Zenabis Global Inc. from HEXO Corp. (TSX:HEXO).

HEXO Corp. Announces CFO Changes, Effective May 16, 2022

HEXO Corp. Announces to Close Its Belleville Facility and Transition Its Operations

Forecast to breakeven in 2024

High number of new and inexperienced directors

Consensus EPS estimates fall by 718%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

HEXO Corp. Announces Refreshed Board of Directors

HEXO Provides Nasdaq Listing Update

Olegna Holdings Inc acquired a 25% stake in Belleville Complex Inc from HEXO Corp. (TSX:HEXO) for $10.1 million.

High number of new directors

Consensus revenue estimates fall by 12%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HEXO Corp. Reports Impairment Charges for the First Quarter Ended October 31, 2021

The Consensus EPS Estimates For HEXO Corp. (TSE:HEXO) Just Fell Dramatically

Price target decreased to CA$2.61

High number of new directors

Director & Co-Founder Sebastien St-Louis has left the company

Independent Chairman of the Board recently bought CA$260k worth of stock

Full year 2021 earnings released: CA$0.90 loss per share (vs CA$7.06 loss in FY 2020)

Full year 2021 earnings released: CA$0.90 loss per share (vs CA$7.06 loss in FY 2020)

Price target decreased to CA$4.95

Price target decreased to CA$6.12

HEXO Corp. (TSX:HEXO) completed the acquisition of 48North Cannabis Corp. (TSXV:NRTH) from Canopy Growth Corporation (TSX:WEED), Wallington Investment Holdings Limited and others.

HEXO Corp. (TSX:HEXO) completed the acquisition of 9037136 Canada Inc. (“Redecan”) from Will Montour, Pete Montour and family.

Price target decreased to CA$7.61

Does HEXO (TSE:HEXO) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: CA$0.17 loss per share (vs CA$0.26 loss in 3Q 2020)

HEXO Corp. Reports Impairment of Property, Plant and Equipment for the Third Quarter Ended April 30, 2021

Price target decreased to CA$8.75

Consensus revenue estimates fall to CA$119.5m

HEXO Corp. Wins Dismissal of Ny State Court Shareholder Class Action

Forecast to breakeven in 2023

HEXO Corp. (TSX:HEXO) completed the acquisition of Zenabis Global Inc. (TSX:ZENA).

HEXO Corp. (TSX:HEXO) entered into a definitive agreement to acquire 9037136 Canada Inc. from Will Montour, Pete Montour and family for approximately CAD 950 million.

HEXO Corp. (TSX:HEXO) agreed to acquire US Production Facility In Colorado.